Bisgaard Bengtsen Mads, Møller Niels
Department of Endocrinology and Internal Medicine, Aarhus University Hospital, 8200 Aarhus N, Denmark.
J Endocr Soc. 2022 Aug 9;6(10):bvac123. doi: 10.1210/jendso/bvac123. eCollection 2022 Oct 1.
Iatrogenic hypoglycemia remains one of the leading hindrances of optimal glycemic management in insulin-treated diabetes. Recurring hypoglycemia leads to a condition of hypoglycemia-associated autonomic failure (HAAF). HAAF refers to a combination of (i) impaired hormonal counterregulatory responses and (ii) hypoglycemia unawareness to subsequent hypoglycemia, substantially increasing the risk of severe hypoglycemia. Several studies since the 1990s have experimentally induced HAAF, yielding variable results.
The aim of this review was to assess the varying designs, clinical outcomes, potential assets, and drawbacks related to these studies.
A systemic literature search was conducted on PubMed and Embase in winter 2021 to include all human studies attempting to experimentally induce HAAF. In different combinations, the search terms used were "hypoglycemia-associated autonomic failure," "HAAF," "hypoglycemia," "recurring," "recurrent," "repeated," "consecutive," and "unawareness," yielding 1565 publications. Inclusion criteria were studies that had aimed at experimentally inducing HAAF and measuring outcomes of hormonal counterregulation and awareness of hypoglycemia.
The literature search yielded 27 eligible publications, of which 20 were successful in inducing HAAF while statistical significantly impairing hormonal counterregulation impairing awareness of hypoglycemia to subsequent hypoglycemia. Several factors were of significance as regards inducing HAAF: Foremost, the duration of antecedent hypoglycemia should be at least 90 minutes and blood glucose should be maintained below 3.4 mmol/L. Other important factors to consider are the type of participants, insulin dosage, and the risk of unintended hypoglycemia prior to the study.
Here we have outlined the most important factors to take into consideration when designing a study aimed at inducing HAAF, including to take into consideration other disease states susceptible to hypoglycemia, thus hopefully clarifying the field and allowing qualified studies in the future.
医源性低血糖仍然是胰岛素治疗糖尿病患者实现最佳血糖管理的主要障碍之一。反复发生的低血糖会导致低血糖相关自主神经功能衰竭(HAAF)。HAAF是指以下两种情况的组合:(i)激素反调节反应受损;(ii)对后续低血糖缺乏低血糖意识,这会大幅增加严重低血糖的风险。自20世纪90年代以来,多项研究通过实验诱导出了HAAF,但结果各不相同。
本综述旨在评估这些研究的不同设计、临床结果、潜在优点和缺点。
2021年冬季,我们在PubMed和Embase上进行了系统的文献检索,纳入所有试图通过实验诱导HAAF的人体研究。检索词以不同组合形式使用,包括“低血糖相关自主神经功能衰竭”“HAAF”“低血糖”“反复”“复发”“重复”“连续”和“无察觉”,共检索到1565篇文献。纳入标准为旨在通过实验诱导HAAF并测量激素反调节结果和低血糖意识的研究。
文献检索得到27篇符合条件的出版物,其中20篇成功诱导出HAAF,同时在统计学上显著损害了激素反调节功能,并降低了对后续低血糖的低血糖意识。在诱导HAAF方面,有几个因素很重要:首先,前期低血糖的持续时间应至少为90分钟,血糖应维持在3.4 mmol/L以下。其他需要考虑的重要因素包括参与者类型、胰岛素剂量以及研究前意外低血糖的风险。
在此,我们概述了设计旨在诱导HAAF的研究时需要考虑的最重要因素,包括考虑其他易发生低血糖的疾病状态,从而有望厘清该领域,并为未来开展高质量研究提供帮助。